Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Pharmarise Holdings Corp (2796)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
657.0 0.0    0.00%
08/05 - Closed. Currency in JPY ( Disclaimer )
Type:  Equity
Market:  Japan
ISIN:  JP3802320006 
  • Volume: 5,100
  • Bid/Ask: 657.0 / 659.0
  • Day's Range: 656.0 - 659.0
Pharmarise Holdings 657.0 0.0 0.00%

2796 Balance Sheet

 
Featured here, the Balance Sheet for Pharmarise Holdings Corp, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
Advanced Balance Sheet
Period Ending: 2024
29/02
2023
30/11
2023
31/08
2023
31/05
Total Current Assets 11761 10875 11532 11372
Cash and Short Term Investments 5164 4923 4877 4742
Cash - - - -
Cash & Equivalents 5164 4923 4877 4742
Short Term Investments - - - 8
Total Receivables, Net 2904 3108 3262 4017
Accounts Receivables - Trade, Net 636 626 574 605
Total Inventory 3329 2494 3088 2290
Prepaid Expenses - - - -
Other Current Assets, Total 364 350 305 323
Total Assets 26425 22966 23553 23421
Property/Plant/Equipment, Total - Net 6077 6098 6054 6010
Property/Plant/Equipment, Total - Gross - - - 12128
Accumulated Depreciation, Total - - - -6121
Goodwill, Net 2509 2602 2612 2748
Intangibles, Net 538 531 526 502
Long Term Investments 5538 2858 2828 2008
Note Receivable - Long Term 2268 2482 2688 3412
Other Long Term Assets, Total 2 2 1 2
Other Assets, Total 789 -264 131 -625
Total Current Liabilities 8724 8241 9861 9835
Accounts Payable 4917 4417 4919 4252
Payable/Accrued - - - -
Accrued Expenses 279 45 273 805
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 2263 1738 3308 3677
Other Current liabilities, Total 1265 2041 1361 1101
Total Liabilities 18472 14576 16572 16436
Total Long Term Debt 8300 4905 5327 5461
Long Term Debt 8300 4905 5327 5216
Capital Lease Obligations - - - 245
Deferred Income Tax - - - -
Minority Interest 81 79 109 105
Other Liabilities, Total 1367 -5292 1275 -6189
Total Equity 7953 8390 6981 6985
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 1961 1961 1298 1298
Additional Paid-In Capital 2177 2177 1553 1553
Retained Earnings (Accumulated Deficit) 4059 4156 4005 4014
Treasury Stock - Common -550 -210 -210 -210
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 306 306 335 330
Total Liabilities & Shareholders' Equity 26425 22966 23553 23421
Total Common Shares Outstanding 11.24 11.74 9.43 9.43
Total Preferred Shares Outstanding - - - -
* In Millions of JPY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

2796 Comments

Write your thoughts about Pharmarise Holdings Corp
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email